Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
Yet Haven collapsed in 2021, falling victim to the very perverse incentives and fragmented local structures it sought to overcome.
As Professor Scott Snyder observed, given the tremendous training, process discipline, and specialization needed to deliver high-quality care,
and the natural risk aversion with patient lives at stake, attempts to reinvent or circumvent the traditional care delivery system have typically failed.
Even Apple's health care ambitions, while not outright failures,
have fallen far short of CEO Tim Cook's 2019 proclamation that if you zoom out into the future and you look back and you ask the question, what was Apple's greatest contribution to mankind?
It will be about health.
While the Apple Watch includes health sensors and has found some clinical applications, it has not transformed healthcare delivery or clinical practice in the revolutionary way Cook promised.
These failures share common threads.
Silicon Valley has repeatedly stormed into healthcare with the hubris of outsiders attempting to reinvent a system they do not fully understand, failing to learn from past mistakes.
The repeated patterns suggest not mere execution challenges, but systemic misunderstanding of what's actually limiting medical progress.
The AI Drug Discovery Reality Check If established tech giants with unlimited resources have failed in healthcare, perhaps specialized AI companies would succeed.
The story of AI drug discovery from 2013 to present suggests otherwise.
It's largely been a story of disappointment relative to the hype.
The term tech bio emerged to rebrand biotech, asserting the importance of the tech by putting it first.
As a head of the UK Bioindustry Association acknowledged in 2024,
I see tech bio as a state of mind, an approach emerging in companies large and small at the interface of data, AI, life science, and innovation.
Companies leading the tech bio movement were primarily AI drug discovery startups.
Industry pioneer Recursion Pharmaceuticals, founded in 2013, centered its mission on realizing a tech biofuture.
It promised to use AI to discover drugs faster and more efficiently than traditional approaches.
Accenture and benevolent AI were other early leaders, attracting significant investment and generating substantial media attention with their promises of AI-revolutionized drug discovery.
Showing 781–800 of 1,653 · page 40 of 83
← Previous
Next →